{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:52:19Z","timestamp":1793022739374,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12325-019-01106-1","type":"journal-article","created":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T10:12:35Z","timestamp":1570702355000},"page":"3368-3380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Yanling","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6223-4799","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjie","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5578-6157","authenticated-orcid":false,"given":"Jihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"1106_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1106_CR2","doi-asserted-by":"crossref","unstructured":"Burges A, Schmalfeldt B. Ovarian Cancer. Dtsch Aerzteblatt Online. 2011. \nhttps:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0635\n\n. Accessed 25 Feb 2019.","DOI":"10.3238\/arztebl.2011.0635"},{"key":"1106_CR3","unstructured":"The World Ovarian Cancer Coalation atlas: global trends in incidence, mortality, and survival. World Ovarian Cancer Coalition. 2018.\nhttps:\/\/worldovariancancercoalition.org\/wp-content\/uploads\/2018\/10\/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018.pdf\n\n. Accessed  25 Feb 2019."},{"key":"1106_CR4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10937400701876095","volume":"11","author":"F Salehi","year":"2008","unstructured":"Salehi F, Dunfield L, Phillips KP, Krewski D, Vanderhyden BC. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors. J Toxicol Environ Health B Crit Rev. 2008;11:301\u201321.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"1106_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","volume":"14","author":"M Fung-Kee-Fung","year":"2007","unstructured":"Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195\u2013208.","journal-title":"Curr Oncol"},{"key":"1106_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5732\/cjc.014.10278","volume":"34","author":"JA L\u00f3pez-Guerrero","year":"2015","unstructured":"L\u00f3pez-Guerrero JA, Romero I, Poveda A. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer. Chin J Cancer. 2015;34:41\u20139.","journal-title":"Chin J Cancer"},{"key":"1106_CR7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/14656566.6.5.743","volume":"6","author":"Y Kikuchi","year":"2005","unstructured":"Kikuchi Y, Kita T, Takano M, Kudoh K, Yamamoto K. Treatment options in the management of ovarian cancer. Expert Opin Pharmacother. 2005;6:743\u201354.","journal-title":"Expert Opin Pharmacother"},{"key":"1106_CR8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460\u20135.","journal-title":"J Clin Oncol"},{"key":"1106_CR9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2009.04.012","volume":"114","author":"M Markman","year":"2009","unstructured":"Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175\u00a0mg\/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114:195\u20138.","journal-title":"Gynecol Oncol"},{"key":"1106_CR10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000320579","volume":"78","author":"LN Abaid","year":"2010","unstructured":"Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV, Markman M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology. 2010;78:389\u201393.","journal-title":"Oncology"},{"key":"1106_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","volume":"24","author":"J Morales","year":"2014","unstructured":"Morales J, Li L, Fattah FJ, et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr. 2014;24:15\u201328.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"1106_CR12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc3748","volume":"14","author":"S Vyas","year":"2014","unstructured":"Vyas S, Chang P. New PARP targets for cancer therapy. Nat Rev Cancer. 2014;14:502\u20139.","journal-title":"Nat Rev Cancer"},{"key":"1106_CR13","doi-asserted-by":"crossref","unstructured":"Lesueur P, Chevalier F, Austry J-B, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8. \nhttp:\/\/www.oncotarget.com\/fulltext\/19079\n\n. Accessed  25 Feb 2019.","DOI":"10.18632\/oncotarget.19079"},{"key":"1106_CR14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33:244\u201350.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1106_CR15","doi-asserted-by":"publisher","first-page":"Suppl 5001","DOI":"10.1200\/jco.2012.30.15_suppl.5001","volume":"30","author":"AM Oza","year":"2012","unstructured":"Oza Amit M, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin (P\/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol. 2012;30(15):Suppl 5001. \nhttps:\/\/doi.org\/10.1200\/jco.2012.30.15_suppl.5001\n\n.","journal-title":"J Clin Oncol"},{"key":"1106_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16:87\u201397.","journal-title":"Lancet Oncol"},{"key":"1106_CR17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392.","journal-title":"N Engl J Med"},{"key":"1106_CR18","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","volume":"21","author":"S Kummar","year":"2015","unstructured":"Kummar S, Oza AM, Fleming GF, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015;21:1574\u201382.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1106_CR19","first-page":"619","volume":"32","author":"EM Swisher","year":"2014","unstructured":"Swisher EM, McNeish IA, Coleman RL, et al. ARIEL 2\/3: an integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. J Clin Oncol. 2014;32(5):619.","journal-title":"J Clin Oncol"},{"key":"1106_CR20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","volume":"119","author":"M Friedlander","year":"2010","unstructured":"Friedlander M, Hancock KC, Rischin D, et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol. 2010;119:32\u20137.","journal-title":"Gynecol Oncol"},{"key":"1106_CR21","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1200\/jco.2008.26.15_suppl.5521","volume":"26","author":"HW Hirte","year":"2008","unstructured":"Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol. 2008;26:5521.","journal-title":"J Clin Oncol"},{"key":"1106_CR22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol"},{"key":"1106_CR23","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"1106_CR24","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","volume":"29","author":"JA Ledermann","year":"2011","unstructured":"Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29:3798\u2013804.","journal-title":"J Clin Oncol"},{"key":"1106_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"1106_CR26","unstructured":"R package: Gemtc.. \nhttp:\/\/cran.r-project.org\/web\/packages\/gemtc\/index.html\n\n. Accessed 25 Feb 2019."},{"key":"1106_CR27","unstructured":"Comparing Frequencies Rate Ratios. \nhttp:\/\/sphweb.bumc.bu.edu\/otlt\/MPH-Modules\/QuantCore\/PH717_ComparingFrequencies\/PH717_ComparingFrequencies9.html\n\n. Accessed 25 Feb 2019."},{"key":"1106_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-54","author":"BS Woods","year":"2010","unstructured":"Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010. \nhttps:\/\/doi.org\/10.1186\/1471-2288-10-54\n\n.","journal-title":"BMC Med Res Methodol"},{"key":"1106_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1200\/jco.2014.55.7348","volume":"5","author":"A du Bois","year":"2014","unstructured":"du Bois A, Floquet A, Kim J-W, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol [Internet]. 2014;5:5. \nhttps:\/\/doi.org\/10.1200\/jco.2014.55.7348\n\n.","journal-title":"J Clin Oncol"},{"key":"1106_CR30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","volume":"17","author":"A du Bois","year":"2016","unstructured":"du Bois A, Kristensen G, Ray-Coquard I, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17:78\u201389.","journal-title":"Lancet Oncol"},{"key":"1106_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2013.04.011","volume":"130","author":"TJ Herzog","year":"2013","unstructured":"Herzog TJ, Scambia G, Kim B-G, et al. A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013;130:25\u201330.","journal-title":"Gynecol Oncol"},{"key":"1106_CR32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2010.34.3178","volume":"30","author":"BY Karlan","year":"2012","unstructured":"Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30:362\u201371.","journal-title":"J Clin Oncol"},{"key":"1106_CR33","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","volume":"387","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387:1066\u201374.","journal-title":"Lancet"},{"key":"1106_CR34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","volume":"143","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Poveda A, Vergote I, et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol. 2016;143:27\u201334.","journal-title":"Gynecol Oncol"},{"key":"1106_CR35","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"1106_CR36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","volume":"16","author":"S Pignata","year":"2015","unstructured":"Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16:561\u20138.","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1106_CR37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ijgc-00009577-200602001-00012","volume":"16","author":"G Bolis","year":"2006","unstructured":"Bolis G, Danese S, Tateo S, et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer. 2006;16(Suppl 1):74\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"1106_CR38","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1200\/JCO.2004.09.088","volume":"22","author":"S De Placido","year":"2004","unstructured":"De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin\/paclitaxel in patients with ovarian cancer: multicenter Italian trials in ovarian cancer (MITO-1) randomized study. J Clin Oncol. 2004;22:2635\u201342.","journal-title":"J Clin Oncol"},{"key":"1106_CR39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2011.03.013","volume":"122","author":"RS Mannel","year":"2011","unstructured":"Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel\u2009\u00d7\u20093 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122:89\u201394.","journal-title":"Gynecol Oncol"},{"key":"1106_CR40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.7150\/ijms.1.116","volume":"1","author":"MO Nicoletto","year":"2004","unstructured":"Nicoletto MO, Tumolo S, Falci C, et al. A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission? Int J Med Sci. 2004;1:116\u201325.","journal-title":"Int J Med Sci"},{"key":"1106_CR41","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2009.21.9691","volume":"27","author":"S Pecorelli","year":"2009","unstructured":"Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel\/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009;27:4642\u20138.","journal-title":"J Clin Oncol"},{"key":"1106_CR42","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djj296","volume":"98","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036\u201345.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"1106_CR43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/ijgc-00009577-200311001-00012","volume":"13","author":"MJ Piccart","year":"2003","unstructured":"Piccart MJ, Floquet A, Scarfone G, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003;13(Suppl 2):196\u2013203.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1106_CR44","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1525-1438.2003.13193.x","volume":"13","author":"B. Sorbe","year":"2003","unstructured":"Sorbe B, Swedish-Norgewian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 2003;13:278\u201386.","journal-title":"International Journal of Gynecological Cancer"},{"key":"1106_CR45","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"1106_CR46","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"1106_CR47","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"1106_CR48","doi-asserted-by":"publisher","unstructured":"Chen H, Fang F, Liu GJ, Xie HY, Zou J, Feng D. Maintenance chemotherapy for ovarian cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. Cochrane Database Syst Rev. 2013. \nhttps:\/\/doi.org\/10.1002\/14651858.CD007414.pub3\n\n. Accessed 11 Jun 2018.","DOI":"10.1002\/14651858.CD007414.pub3"},{"key":"1106_CR49","doi-asserted-by":"publisher","unstructured":"Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. Cochrane Database Syst Rev. 2011. \nhttps:\/\/doi.org\/10.1002\/14651858.CD007930.pub2\n\n. Accessed 12 Jun 2018.","DOI":"10.1002\/14651858.CD007930.pub2"},{"key":"1106_CR50","doi-asserted-by":"publisher","unstructured":"Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group. Cochrane Database Syst Rev. 2015. \nhttps:\/\/doi.org\/10.1002\/14651858.CD007929.pub3\n\n. Accessed 12 Jun 2018.","DOI":"10.1002\/14651858.CD007929.pub3"},{"key":"1106_CR51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","volume":"4","author":"P Jagtap","year":"2005","unstructured":"Jagtap P, Szab\u00f3 C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1106_CR52","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1158\/1078-0432.CCR-06-2260","volume":"13","author":"K Ratnam","year":"2007","unstructured":"Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res. 2007;13:1383\u20138.","journal-title":"Clin Cancer Res"},{"key":"1106_CR53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s12094-008-0207-8","volume":"10","author":"A Peralta-Leal","year":"2008","unstructured":"Peralta-Leal A, Rodr\u00edguez MI, Oliver FJ. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol. 2008;10:318\u201323.","journal-title":"Clin Transl Oncol"},{"key":"1106_CR54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"1106_CR55","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"issue":"1","key":"1106_CR56","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1259\/bjr\/99111297","volume":"81","author":"S Kyle","year":"2008","unstructured":"Kyle S, Thomas HD, Mitchell J, Curtin NJ. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer. Br J Radiol. 2008;81(1):S6\u201311.","journal-title":"Br J Radiol"},{"key":"1106_CR57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/cancers10120487","volume":"10","author":"I Faraoni","year":"2018","unstructured":"Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers. 2018;10:487.","journal-title":"Cancers"},{"key":"1106_CR58","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","volume":"105","author":"M Javle","year":"2011","unstructured":"Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011;105:1114\u201322.","journal-title":"Br J Cancer"},{"key":"1106_CR59","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","volume":"28","author":"BTJ Hennessy","year":"2010","unstructured":"Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570\u20136.","journal-title":"J Clin Oncol"},{"key":"1106_CR60","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.coph.2005.03.006","volume":"5","author":"N Turner","year":"2005","unstructured":"Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol. 2005;5:388\u201393.","journal-title":"Curr Opin Pharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01106-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01106-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T23:25:58Z","timestamp":1602199558000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01106-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01106-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]},"assertion":[{"value":"26 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}